Product

Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine

Aliases

Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)

2 clinical trials

1 indication

Indication

Clinical trial

A Randomized, Double-blind, Active-controlled Clinical Study Evaluating the Immunogenicity and Safety of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells) in People 18 Years of Age and Older

Status: Active (not recruiting), Estimated PCD: 2023-10-30

Clinical trial

A Randomized, Double-blind, Active-controlled Clinical Study Evaluating the Immunogenicity and Safety of Omicron BA.4/5-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO Cells) in People Aged 18 Years and Older With Different Immunization Programs

Status: Not yet recruiting, Estimated PCD: 2024-05-15